• (PLX AI) – Allarity Therapeutics A/S, a Danish clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers, and Lonza today announced an agreement to develop and manufacture dovitinib.
  • • The agreement aims to commence manufacturing of dovitinib in 2022 to meet Allarity’s projected needs for bringing dovitinib to market following anticipated regulatory approvals
  • • Planned NDA filing in 2021

Quelle: PLX AI